Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).
Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY.
Galanis E, et al. Among authors: buckner jc.
Neurooncol Adv. 2022 Apr 4;4(1):vdac041. doi: 10.1093/noajnl/vdac041. eCollection 2022 Jan-Dec.
Neurooncol Adv. 2022.
PMID: 35664553
Free PMC article.